Guidance Capital Inc. Raises Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Guidance Capital Inc. grew its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 12.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,417 shares of the company’s stock after purchasing an additional 941 shares during the period. Guidance Capital Inc.’s holdings in Amphastar Pharmaceuticals were worth $343,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. McGlone Suttner Wealth Management Inc. purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter worth about $28,000. Principal Securities Inc. purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at approximately $34,000. Quadrant Capital Group LLC lifted its stake in shares of Amphastar Pharmaceuticals by 27.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after purchasing an additional 223 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 115.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock valued at $150,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Leeward Financial Partners LLC purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter worth $217,000. Institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AMPH. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, May 22nd. Piper Sandler reissued an “overweight” rating and set a $71.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Thursday. JPMorgan Chase & Co. started coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 target price for the company. Finally, StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $66.00.

Amphastar Pharmaceuticals Stock Down 0.9 %

NASDAQ:AMPH traded down $0.35 on Friday, reaching $40.00. 602,875 shares of the stock traded hands, compared to its average volume of 329,925. The company has a current ratio of 2.18, a quick ratio of 1.72 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of 13.84, a PEG ratio of 0.83 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 12 month low of $38.43 and a 12 month high of $67.66. The company’s fifty day simple moving average is $41.61 and its 200 day simple moving average is $47.85.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.20. Amphastar Pharmaceuticals had a net margin of 22.88% and a return on equity of 29.17%. The firm had revenue of $171.84 million for the quarter, compared to analysts’ expectations of $171.13 million. Equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 3,596 shares of the company’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the transaction, the chief financial officer now directly owns 94,103 shares of the company’s stock, valued at $3,851,635.79. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the sale, the director now directly owns 78,409 shares in the company, valued at $3,246,132.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William J. Peters sold 3,596 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at approximately $3,851,635.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,096 shares of company stock valued at $335,259. Corporate insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.